Novo Nordisk A/S - Reduction of the share capital
Bagsværd, Denmark, 18 April 2016 - At Novo Nordisk's Annual General Meeting on 18 March 2016, it was decided to reduce the company's B share capital from DKK 412,512,800 to DKK 402,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each.
Further information
| Media: | ||
| Anne Margrethe Hauge | +45 3079 3450 | amhg@novonordisk.com |
| Investors: |
||
| Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
| Daniel Bohsen | +45 3079 6376 | dabo@novonordisk.com |
| Melanie Raouzeos | +45 3075 3479 | mrz@novonordisk.com |
| Kasper Veje | +45 3079 8519 | kpvj@novonordisk.com |
Company announcement No 29 / 2016
Company announcement No 29 / 2016
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire
HUG#2004301
\Hugin